Tumor metastasis: mechanistic insights and clinical challenges

PS Steeg - Nature medicine, 2006 - nature.com
Metastatic disease is the primary cause of death for most cancer patients. Complex and
redundant pathways involving the tumor cell and the microenvironment mediate tumor …

[HTML][HTML] Downregulation of MTAP promotes tumor growth and metastasis by regulating ODC activity in breast cancer

Y Zhang, TT Zhang, L Gao, YN Tan, YT Li… - … Journal of Biological …, 2022 - ncbi.nlm.nih.gov
Methylthioadenosine phosphorylase (MTAP) is a key enzyme in the methionine salvage
pathway and has been reported to suppress tumorigenesis. The MTAP gene is located at …

DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma

DLT Koomoa, D Geerts, I Lange… - International …, 2013 - spandidos-publications.com
Neuroblastoma (NB) is the most common extracranial pediatric tumor. NB patients over 18
months of age at the time of diagnosis are often in the later stages of the disease, present …

Metastasis models: the green fluorescent revolution?

S Paris, R Sesboüé - Carcinogenesis, 2004 - academic.oup.com
Metastases are the leading cause of treatment failure and death of patients affected by
malignant tumors, which makes them a major therapeutic target. During the last decade …

[HTML][HTML] Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss

MB Zerdan, PA Kumar, E Haroun, N Srivastava… - Oncotarget, 2023 - ncbi.nlm.nih.gov
Introduction: Homozygous deletion of MTAP upregulates de novo synthesis of purine
(DNSP) and increases the proliferation of neoplastic cells. This increases the sensitivity of …

Inhibitors of polyamine biosynthesis decrease the expression of the metalloproteases meprin α and MMP-7 in hormone-independent human breast cancer cells

GL Matters, A Manni, JS Bond - Clinical & experimental metastasis, 2005 - Springer
Inhibition of ornithine decarboxylase (ODC), a key enzyme in polyamine biosynthesis, by the
irreversible inhibitor α-difluoromethylornithine (DFMO) has been shown to decrease the …

Preclinical drug development must consider the impact on metastasis

PS Steeg, RL Anderson, M Bar-Eli, AF Chambers… - Clinical Cancer …, 2009 - AACR
Recently, two landmark reports on antiangiogenic therapy were published: Paez-Ribes and
colleagues (1) and Ebos and colleagues (2). The Board of the Metastasis Research Society …

Metastasis of hormone-independent breast cancer to lung and bone is decreased by α-difluoromethylornithine treatment

MM Richert, PA Phadke, G Matters… - Breast Cancer …, 2005 - Springer
Introduction Polyamines affect proliferation, differentiation, migration and apoptosis of cells,
indicating their potential as a target for cancer chemotherapy. Ornithine decarboxylase …

Cellular mechanisms mediating the anti-invasive properties of the ornithine decarboxylase inhibitor α-difluoromethylornithine (DFMO) in human breast cancer cells

A Manni, S Washington, D Mauger, DA Hackett… - Clinical & experimental …, 2004 - Springer
We have shown that inhibition of polyamine biosynthesis with α-difluoromethylornithine
(DFMO) reduces in vitro invasiveness and metastatic capacity of MDA-MB-435 breast cancer …

Effects of polyamine synthesis inhibitors on primary tumor features and metastatic capacity of human breast cancer cells

A Manni, S Washington, X Hu, JW Griffith… - Clinical & experimental …, 2005 - Springer
We have previously reported that inhibition of polyamine biosynthesis with α-
difluoromethylornithine (DFMO) reduces pulmonary metastasis from MDA-MB-435 human …